Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange

Hannover Medical School (MHH)

Status: Terminated

Conditions: Clotting Disorder Due to Plasma Exchange Therapy; Humoral Rejection After Kidney Transplantation

Study type: Observational

Funder types: Other

Identifiers

NCT02095821

FIB-2110-2014

Details and patient eligibility

About

Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. Treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. However, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. In the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• plasma exchange therapy due to humoral rejection after kidney transplantation

Exclusion criteria

• hereditary coagulopathy
• chronic liver disease (Child C)
• therapeutic anticoagulation
• malnutrition (BMI<17.5)

Trial design

2 participants in 1 patient group

Humoral rejection, TPE